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Abstract
Background The pathogenesis of inflammatory bowel
disease (IBD) is complex and multifaceted including ge-
netic predisposition, environmental components, microbial
dysbiosis, and inappropriate immune activation to micro-
bial components. Pathogenic bacterial provocateurs like
adherent and invasive E. coli have been reported to in-
crease susceptibility to Crohn’s disease. Serum-derived
bovine immunoglobulin/protein isolate (SBI) is comprised
primarily of immunoglobulins (Igs) that bind to conserved
microbial components and neutralize exotoxins.
Aim To demonstrate that oral administration of SBI may
modulate mucosal inflammation following colonization
with E. coli, LF82, and exposure to dextran sodium sulfate
(DSS).
Methods Defined microbiota mice harboring the altered
Schaedler flora (ASF) were administered SBI or hy-
drolyzed collagen twice daily starting 7 days prior to
challenge with E. coli LF82 and continuing for the re-
mainder of the experiment. Mice were treated with DSS for
7 days and then evaluated for evidence of local and pe-
ripheral inflammation.
Results Igs within SBI bound multiple antigens from all
eight members of the ASF and E. coli LF82 by western blot
analysis. Multiple parameters of LF82/DSS-induced colitis
were reduced following administration of SBI, including
histological lesion scores, secretion of cytokines and
chemokines from cecal biopsies, intestinal fatty acid
binding protein (I-FABP) and serum amyloid A from
plasma.
Conclusions Oral administration of SBI attenuated clin-
ical signs of LF82/DSS-induced colitis in mice. The data
are consistent with the hypothesis that SBI im-
munoglobulin binding of bacterial antigens in the intestinal
lumen may inhibit the inflammatory cascades that con-
tribute to IBD, thus attenuating DSS-induced colitis.
Keywords Inflammatory bowel disease (IBD)  Dextran
sulfate sodium (DSS)  Microbiota  Bovine
immunoglobulin  Serum
Introduction
Inflammatory bowel diseases (IBD), including Crohn’s
disease (CD) and ulcerative colitis (UC), are a group of
chronic intestinal disorders with a multifactorial etiology
that involves complex interactions between the (GI) mi-
crobiota, genetics, environment, and the immune system
[1]. The human GI tract is home to a diverse population of
bacteria that reaches 1012 cells/gram contents in the colon
[2–4]. Alterations in the gut microbiota (i.e., dysbiosis)
resulting in a loss in microbial diversity are believed to
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contribute to an exaggerated adaptive immune response,
further complicating the disease [5]. In addition, bacterial
components or microbial-associated molecular patterns
(MAMPS) have been shown to exacerbate the inflamma-
tion associated with IBD [6]. Mice with genetic suscepti-
bilities to IBD (e.g., IL-10-/-) do not develop IBD in a
germfree environment [7]. However, germfree SAMP1/Yit
mice develop spontaneous colitis and severe inflammation
when housed in conventional environments [8].
Bacterial pathogens have been postulated to contribute
to the severity of IBD. Notably adherent-invasive E. coli
(AIEC) E. coli has been reported to enhance the patho-
genesis and chronicity of adult and pediatric CD [9–14]. A
well-characterized AIEC isolate, LF82, has been reported
to increase colitis severity in mice administered DSS [15].
Several mechanisms might explain how AIEC contributes
to the pathogenesis of CD, including the presence of type 1
pili that facilitate attachment to mucosa and replication
within host epithelial cells and macrophages without
causing cell death [16, 17]. These mechanisms may con-
tribute to the downstream dysregulated immune reactivity
toward the resident GI microbiota.
Multiple studies have shown that oral administration of
animal plasma can reduce GI enteropathy and restore
homeostasis in animals [18, 19]. SBI is predominantly IgG
([ 50 %) and intended for oral consumption to provide
distinctive nutritional requirements for the clinical dietary
management of specific GI conditions under physician
supervision (e.g., in irritable bowel syndrome with diarrhea
(IBS-D), IBD, and HIV-associated enteropathy) [18]. We
recently demonstrated that SBI binds to microbial com-
ponents resulting in steric and immune exclusion
mechanisms to modulate inflammation [20]. Specifically,
the Ig component of SBI binds bacterial antigens to either
(1) increase the size of the antigen to prevent translocation
across an epithelial membrane (steric exclusion) or (2)
block the recognition sites on antigens that are required to
activate monocytes (immune exclusion) [20]. These in vit-
ro findings supported the rationale that binding microbial
antigens by Igs within SBI may help ameliorate the in-
flammation associated with IBD.
In this study, the impact of oral SBI administration on
downstream intestinal inflammation was assessed in an
LF82/DSS model of IBD. In this model, C3H/HeN mice
harboring a defined intestinal microbiota were colonized
with E. coli LF82 prior to low-dose DSS exposure to in-
duce mucosal inflammation. Our results show that SBI
administration reduced local and systemic inflammation
associated with LF82/DSS-induced colitis. Where bacteri-
al-mediated inflammation is operative in IBD patients, oral
consumption of SBI and its microbial binding components
may provide valuable benefits.
Materials and Methods
Animals
Male and female gnotobiotic C3H/HeN:TAC mice
(12 weeks of age, 25–30 g) harboring the altered Schaedler
flora (ASF) were bred and maintained under gnotobiotic
conditions in flexible film isolators (housed at Iowa State
University). Mice were exposed to a 12-h light/dark cycle,
and an irradiated diet (Harlan 2919) and sterile water were
provided ad libitum. Mice were monitored daily for de-
hydration, activity, ruffled fur, and diarrhea. The ASF
consisted of the following bacterial members: ASF356,
Clostridium sp.; ASF360, Lactobacillus intestinalis;
ASF361, Lactobacillus murinus; ASF457, Mucispirillum
schaedleri; ASF492, Eubacterium plexicaudatum;
ASF500, Pseudoflavonifactor sp.; ASF502, Clostridium
sp.; and ASF519, Parabacteroides goldsteinii [21].
Experimental Design
Methods
ASF C3H/HeN mice received 50 mg of either SBI or HC
as a control protein twice daily (AM and PM) by oral
gavage (100 mg/mouse/day), starting on day -7 for
5 weeks (Fig. 1). SBI was used to target bacterial antigens
in the GI tract that would contribute to inflammation. Ten
percent solutions (10 % w/v) of SBI and HC (10 % protein
w/v) (Entera Health, Inc., Ankeny, IA) were prepared in
PBS, centrifuged, and pre-filtered through a nominal filter
(0.5 lm, Millipore opticap XL 4 capsule #
KWSSA04HH3) followed by a 0.22-lm filter (Nalgene
Fig. 1 Experimental design. Defined microbiota C3H/HeN mice
were gavaged daily with either 100 mg of serum-derived bovine
immunoglobulin/protein isolate (SBI) or hydrolyzed collagen (HC).
One week after protein administration was initiated mice were orally
gavaged with 5 9 108 CFU of E. coli LF82. Low-dose DSS (2 % for
the first 2 days and then 1.5 % for the remaining 5 days) was
administered in drinking water starting 3 weeks after E. coli
colonization. Mice were allowed free access to the DSS for 7 days
prior to necropsy
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#569-0020). Sterility was confirmed on blood agar plates
and trypticase soy broth under aerobic conditions. Solu-
tions of SBI and HC were aseptically transferred into iso-
lators for daily feedings. No adverse events were observed.
Infection With E. coli LF82
One week after administration of SBI and HC, mice were
orally colonized with 5 9 108 CFU of Escherichia coli
LF82 obtained from Dr. Kenny Simpson (Cornell, Ithaca,
NY) which was aerobically maintained on TSA plates at
37 C. On day zero, bacteria were harvested from plates
and suspended in sterile PBS. Quantification of bacteria
was estimated using the McFarland standards and con-
firmed with serial dilution of the inoculum. The suspension
was aseptically transferred into the isolators, and mice were
orally gavaged with 0.2 ml of E. coli LF82 culture
(5 9 108 CFUs). E. coli LF82 colonization was confirmed
at necropsy by standard culture of cecal contents on TSA
and MacConkey plates.
DSS Treatment
DSS (MP Biomedicals, LLC # 160110) was prepared in
sterile water and filtered (0.2 lm) before aseptically
transferred into isolators. Starting 3 weeks after E. coli
colonization, mice received DSS in drinking water for
7 days (2 % for the first 2 days and then 1.5 % for the
remaining 5 days). Mice were allowed to drink DSS water
ad libitum. After euthanasia (CO2 asphyxiation), tissues
were evaluated macroscopically and processed for histo-
pathology, cytokine, and inflammatory marker analysis.
Preparation of Bacterial Antigens for Western Blots
Bacteria (eight ASF members and LF82) were cultivated in
BHI broth supplemented with bovine serum at 37 C in an
anaerobic chamber. Bacteria were harvested, washed in
PBS, frozen, lyophilized, and stored at -20 C. For
western blot analysis, bacteria were resuspended in sterile
PBS (2 mg/ml), frozen, and thawed at -20 and -80 C
twice each, followed by sonication at maximum power on
ice. The lysates were sterilized by ultraviolet irradiation
and sterility confirmed bacteriologically.
Macroscopic Scores
Cecum and colon were harvested at necropsy and scored
for gross inflammatory changes on a binary scale of 0–1 for
the presence/absence of the following criteria: cecal atro-
phy, enlarged cecal tonsil, cecal emptying, abnormally
watery or mucoid intraluminal cecal, and/or colon contents,
luminal blood in cecum, and/or colon, tissue thickening of
cecum, and/or colon, and the absence of formed fecal
pellets in colon. Individual scores were combined (max-
imum score of 10) to derive a macroscopic score.
Histopathological Analysis
Samples of cecum and colon were fixed in 10 % neutral
buffered formalin, paraffin embedded, sectioned, and
stained with hematoxylin and eosin. Tissue sections were
evaluated by a blinded, board-certified veterinary pathol-
ogist (JH). Tissues were scored on severity of ulceration,
inflammation, edema, stromal collapse, gland hyperplasia,
and height of the mucosa. Each criterion was individually
scored on a scale of 0–5, except height of the mucosa
which was measured as the average ratio of crypt height
divided by crypt width (scale of 1–7). The total score is
represented as the sum of all criteria (total score scale of
0–32).
Evaluation of Systemic Inflammatory and Damage
Markers
Plasma samples were obtained at necropsy and stored at
-20 C until analysis. Serum amyloid A (SAA) analysis
was performed using an ELISA kit (Life Technologies,
#KMA0021) at a 1:200 dilution. Intestinal fatty acid
binding protein (I-FABP) in mouse plasma (diluted at
1:500) was assessed by ELISA (MyBioSource,
#MBS702875). Both SAA and I-FABP ELISAs were per-
formed according to the manufacturer’s instructions (mi-
croplate reader—Molecular Devices, Sunnyvale, CA).
Evaluation of Mucosal Cytokine and Chemokine
Levels
One-centimeter cecal tissue biopsies were harvested at
necropsy in triplicate from each animal, washed, and in-
cubated in tissue culture medium (RMPI 1640) plus peni-
cillin, streptomycin, gentamicin, glutamine, pyruvate, and
2-mercaptoethanol at 37 C. Supernatants were harvested
from cecal biopsies at 24 h, and triplicate samples from
individual animals were pooled and frozen at -20 C until
analysis. A multiplex bead-based assay from Bio-Rad (Bio-
Plex ProTM, Bio-Rad, Hercules, CA) assessed levels of
mouse cytokines/chemokines including IL-6, G-CSF, and
CCL5 using a Bio-Plex MAGPIXTM Multiplex Reader,
Bio-Rad.
Western Blot
ASF and LF82 bacterial antigens were standardized for
protein content by BCA protein assay (Pierce, Rockford,
IL, #23227). Antigen samples (5 lg) were reduced by
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boiling in LDS buffer (Life Technologies, #NP0008) and
Bolt reducing agent (Life Technologies, #B0009) and
separated on 4–12 % Bis/Tris gels (Life Technologies,
#NP0336PK2). Gels were silver stained to demonstrate
equalized protein and loading. Following confirmation of
equal protein by BCA and silver stain, additional gels were
blotted onto a PVDF membrane and blocked with Pierce
protein-free T20 blocking buffer. The membrane was then
blotted with 0.1 % SBI overnight and incubated with rabbit
anti-bovine IgG HRP at 1:25,000 (Sigma, #A5295). The
blot was visualized with SuperSignal West Pico chemilu-
minescent substrate (Pierce, #34087) using a C-DiGit (LI-
COR, Lincoln, NE).
Statistical Analysis
Actual mice used per treatment group were as follows: (1)
HC/LF82 = 7, (2) HC/LF82 ? DSS = 10, (3) SBI/
LF82 = 8, and (4) SBI/LF82 ? DSS = 11. All mice were
analyzed for each assay. Mice were assigned to a treatment
group based on sex and number of mice per cage. The
order in which the mice were treated each day rotated
between the various cages. A two-way analysis of variance
(ANOVA) was performed on all four treatment groups
(7–11 mice per group), and t-tests were utilized when
significantly different groups were identified by ANOVA.
Each mouse was an experimental unit.
Ethical Considerations
All mouse experiments were performed according to the
requirements of the Iowa State University Institutional
Animal Care and Use Committee (IACUC) with the fol-
lowing approval number: 9-04-5755-M.
Results
Colonization of Defined Microbiota C3H Mice
with E. coli LF82
Prior to treatments, all mice were healthy and free of ex-
traneous contaminants. Gnotobiotic C3H/HeN:TAC mice
harboring the ASF became chronically colonized with
E. coli LF82 after a single oral gavage. At necropsy, all
mice were positive for E. coli LF82 by culture of cecal
contents and CFUs were not altered by DSS administration
(supplemental data, S1). Three environmental aerobic
bacterial contaminants were found to have been uninten-
tionally introduced into the gnotobiotic isolators, Steno-
trophomonas, Pseudomonas, and Acinetobacter. While all
mice were likely exposed to the contaminants, multiple
cultures of fecal/cecal contents were negative for the
growth of these organisms, indicating that the quantity of
vegetative bacteria in the GI tract was too low to culture.
The low abundance of each contaminant (B1 %) was de-
tected in the majority of mice through fecal DNA se-
quencing (data not shown).
Binding of SBI to Altered Schaedler Flora
and E. coli Lysates
SBI predominately consists of IgG ([50 %) and has been
shown to bind and neutralize conserved bacterial antigens
and toxins in vitro [20, 22, 23]. It was hypothesized that
SBI would bind to bacterial antigens in the intestinal lumen
and attenuate the severity of DSS-induced inflammation.
To demonstrate that SBI was capable of binding to ASF
antigens, individual ASF bacterial lysates were separated
by SDS-PAGE, transferred to membranes, and reacted with
SBI. As shown in Fig. 2, bovine (IgG) in SBI recognized
multiple antigenic components from each of the ASF
bacterial lysates and E. coli LF82.
SBI Attenuated Macroscopic and Histological
Changes
LF82/DSS mice administered HC had elevated intestinal
macroscopic scores compared with HC-gavaged mice
colonized with LF82 alone (Fig. 3, p = 0.02). The ad-
ministration of SBI to the LF82/DSS mice trended toward a
reduction in the macroscopic score compared with HC-
gavaged LF82/DSS mice (Fig. 3, p = 0.14). In the absence
of DSS exposure, the observed differences in the macro-
scopic lesions between mice treated with HC or SBI were
minimal (Fig. 3). Colonic and cecal histological scores
were increased in LF82/DSS mice given HC compared
with LF82-colonized mice administered HC (Figs. 4a, b,
5a, b). The DSS-induced histological changes were char-
acterized by increased mucosal height, ulceration, edema,
glandular hyperplasia, as well as increases in inflammatory
cell infiltrate consisting of mononuclear and polymor-
phonuclear leukocytes in the colon and cecum (Figs. 4b,
5b). Administration of SBI lessened the histological
changes in the colon (Fig. 4d) and cecum (Fig. 5d) of
LF82/DSS mice. The overall histopathological score of
LF82/DSS-induced epithelial damage and inflammation in
both the colon (Fig. 4e) and cecum (Fig. 5e) was sig-
nificantly decreased in animals given SBI compared with
those administered HC (p\ 0.05).
Evaluation of Cytokine and Chemokines From
Cecal Biopsies
The release of cytokines and chemokines from cecal explants
was assessed to determine the potential impact of SBI binding
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to bacterial components on mucosal inflammation. The ad-
ministration of SBI to LF82/DSS mice resulted in significant
reductions in IL-6 secretion from cecal biopsies compared
withHC-gavagedmiceLF82/DSS (Fig. 6, p = 0.006). Based
on the increased cellular infiltrate observed in histological
sections of the LF82/DSS mice, the secretion of CCL5 and
G-CSFwas alsomeasured. CCL5 is a chemokine that recruits
monocytes, lymphocytes, mast cells, and eosinophils and has
been shown to be upregulated by cells within the subepithelial
lamina propria following activation by microbial antigens, as
well as by DSS- and TNBS-induced colitis [24, 25]. LF82/
DSS administration increased the secretion of CCL5 from
cecal explants in the HC-treated group (Fig. 7, mean =
108 pg/ml) compared with mice given HC alone (Fig. 7,
mean = 49). Although not statistically significant, there was a
strong trend toward decreased levels of CCL5 in LF82/DSS
mice administered SBI (Fig. 7, mean = 49 pg/ml) that were
similar to levels observed in LF82-colonized mice given HC
(Fig. 7, mean = 49 pg/ml). A similar trend was observed for
G-CSF, a chemokine that functions to recruit and differentiate
granulocytes into neutrophils (Fig. 7, mean of HC and LF82/
DSS = 6569 pg/ml; mean of SBI and LF82/DSS =
5163 pg/ml).
Attenuation of Intestinal Injury with SBI
In clinical and experimental colitis, epithelial cell functions
are altered as a consequence of damage to the gut [26].
I-FABP is a cytoplasmic protein found in epithelial cells of
the small intestine and proximal colon and has proven an
excellent blood biomarker of intestinal injury and ischemia
in IBD [27–29]. Compared with mice treated with HC,
plasma I-FABP levels were found to be significantly de-
creased following SBI administration (Fig. 8, p = 0.03) in
mice colonized with LF82 but not treated with DSS. For
LF82/DSS mice, administration of SBI resulted in sig-
nificantly lowered levels of I-FABP compared with LF82/
DSS mice given HC (Fig. 8, p = 0.0003).
Attenuation of a Systemic Marker of Inflammation
in the Presence of SBI
SAA is an acute-phase protein secreted primarily by the liver
during inflammation. To determine whether peripheral
Fig. 2 SBI binding of altered
Schaedler flora (ASF) and LF82
bacterial antigens. ASF whole-
cell lysates were separated by
SDS-PAGE and transferred to a
nitrocellulose membrane. Lane
1 protein standard, 2 ASF 356, 3
ASF 360, 4 ASF 361, 5 ASF
457, 6 ASF 492, 7 ASF 500, 8
ASF 502, 9 ASF 519, and 10
LF82. Membrane was blotted
with a 0.1 % serum-derived
bovine immunoglobulin/protein
isolate (SBI) solution followed
by a 1:25,000 dilution of anti-
bovine IgG HRP and visualized
with chemiluminescence. Left:
western blot and right: silver
stain
Fig. 3 Intestinal macroscopic score. Scores were evaluated at
necropsy from ASF-harboring mice challenged with E. coli (LF82)
with or without DSS and gavaged with either serum-derived bovine
immunoglobulin (SBI) or hydrolyzed collagen (HC). Scores were
determined by the presence or absence of gross anatomic changes
indicative of inflammatory responses in cecum and colon as described
in ‘‘Materials and Methods’’ section. Two-way ANOVA indicated
that macroscopic score was affected by DSS administration
(p = 0.0005), but not affected by protein choice (p = 0.1947). The
interaction of the two variables on macroscopic score was not
significant (p = 0. 1947) following two-way ANOVA
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inflammation was reduced by administration of SBI, SAA
was analyzed in plasma of LF82/DSS mice administered
either HC or SBI. LF82/DSS mice given HC had sig-
nificantly elevated levels of SAA compared with HC-treated
mice colonized with LF82 alone (Fig. 9, p = 0.002).
However, SAA levels in LF82/DSS mice administered SBI
remained at control levels and were significantly lower than
LF82/DSS mice gavaged with HC (Fig. 9, p = 0.0006).
Fig. 4 Histopathological scores of colon tissue. Colons were recov-
ered from E. coli LF82-colonized defined microbiota mice treated
with a hydrolyzed collagen (HC), b HC ? DSS showing increased
mucosal height, gland hyperplasia, ulcerated bed, swollen endothe-
lium, and some blood, c serum-derived bovine immunoglobulin/
protein isolate (SBI), or d SBI ? DSS depicting less inflammatory
infiltrate, gland hyperplasia, and stromal collapse than HC ? DSS.
e Comparison of histopathological scores among treatment groups;
lesions were scored in a blinded fashion with a maximum histological
score (summation of individual parameters) of 32. Groups with
identical letters are not statistically different from each other
(p B 0.05). All images are 9 400. Two-way ANOVA indicated that
colon scores were affected by both the administration of DSS
(p = 0.0001) and protein choice (p = 0.0435). There was also a
significant interaction found between the two variables on colon score
following two-way ANOVA (p = 0.0253)
Fig. 5 Histopathological scores of cecal tissue. Ceca were recovered
from LF82-colonized defined microbiota mice treated with a hy-
drolyzed collagen (HC), b HC ? DSS depicting severe mucosal
inflammation, characterized by epithelial ulcerations, swollen blood
vessels, loss of glandular structure, and hemorrhage, c serum-derived
bovine immunoglobulin/protein isolate (SBI), or d SBI ? DSS
depicting mild mucosal inflammation and crypt hyperplasia.
e Histopathological scores among treatment groups; lesions were
scored in a blinded fashion with a maximum histological score
(summation of individual parameters) of 32. Groups with identical
letters are not statistically different from each other (p B 0.05). All
images are 9 400. Two-way ANOVA indicated that cecal scores
were affected by the administration of DSS (p = 0.0001), but not
protein choice (p = 0.2780). There was a significant interaction found
between the two variables on cecal score following two-way ANOVA
(p = 0.0220)
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Discussion
As reported previously, SBI has been shown to bind and
neutralize bacterial antigens in vitro resulting in a reduction
in inflammatory cytokines produced from monocytes in a
transwell system [20]. The present study was undertaken to
expand upon those initial findings and to assess the effect
of SBI on inflammation in a mouse model of colitis where a
bacterial provocateur was administered. In experiments
reported here, results indicate a reduction in epithelial
damage as well as decreased mucosal and systemic in-
flammation in LF82/DSS-treated animals when adminis-
tered SBI versus a control protein, HC.
The DSS-induced colitis model in mice was utilized
because it is an analog model for studying human IBD, and
most closely resembles UC [30]. Similar to human UC,
DSS treatment induces epithelial damage, inflammatory
cell infiltrate, and symptoms of watery and/or bloody di-
arrhea [30]. Using a ‘‘multiple-hit’’ colitis model that in-
cludes colonization of defined microbiota mice with a
novel organism (e.g., Helicobacter bilis), previous work
has demonstrated increases in host susceptibility to low-
dose DSS-induced colitis resulting in more severe inflam-
matory changes [32]. E. coli LF82 is an AIEC isolate from
a patient with ileal CD [9, 10]. As previously reported, DSS
treatment increased the severity of colitis in mice colonized
with E. coli LF82, which may be due to the ability of
E. coli LF82 to disrupt the integrity of the epithelial barrier
[15, 33]. In mice harboring a conventional GI microbiota,
E. coli LF82 has not been shown to successfully colonize
without repeated administration [15, 34]. In contrast, de-
fined microbiota mice harboring the ASF become
chronically colonized with E. coli LF82 following a single
oral gavage. Accordingly, E. coli LF82 was used as the
bacterial provocateur in the studies reported here to
Fig. 6 Concentration of IL-6 from cecal biopsies. Culture super-
natants were collected after 24 h of incubation of cecal biopsies in
media collected from E. coli LF82-colonized defined microbiota mice
were treated with hydrolyzed collagen (HC), HC ? DSS, serum-
derived bovine immunoglobulin/protein isolate (SBI), or SBI ? DSS.
Two-way ANOVA indicated that IL-6 concentration was affected by
protein choice (p = 0.0061), but not DSS administration
(p = 0.5442). The interaction of the two variables on IL-6 concen-
tration was not significant (p = 0.3014) following two-way ANOVA.
Further analysis indicated that SBI significantly reduced IL-6
concentration in the LF82/DSS colitis model (HC ? LF82/DSS
compared with SBI ? LF82/DSS, p = 0.006)
Fig. 7 Secretion of G-CSF (a) and CCL5 (b) from cecal biopsies.
Culture supernatants were collected after 24 h of incubation of cecal
biopsies in medium. Tissues were collected from E. coli LF82-
colonized defined microbiota mice treated with hydrolyzed collagen
(HC), HC ? DSS, serum-derived bovine immunoglobulin/protein
isolate (SBI), or SBI ? DSS. For panels A and B, Two-way ANOVA
indicated that the addition of DSS or protein did not significantly alter
secretion of G-CSF or CCL5. Further analysis indicated a strong
trend, but not significant interaction of the two variables on G-CSF
(p = 0.1302) or CCL5 concentration (p = 0.0558)
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heighten the sensitivity of the murine host to low-dose
DSS.
Altered intestinal permeability increases both the sus-
ceptibility to disease and predicts relapse in CD [35, 36].
During both IBD and DSS-induced colitis, the epithelial
barrier is compromised leading to increased epithelial
permeability and translocation of bacterial products [30,
37]. In this study, SBI attenuated epithelial damage in the
LF82/DSS multiple-hit model of colitis, as evidenced by
reduced histopathological lesion scores and reduced
I-FABP compared with mice given HC and LF82/DSS.
I-FABP has been proposed as a plasma biomarker for in-
testinal injury in UC patients since levels were elevated in
patients with severe disease [29]. However, in murine
models, DSS-induced colitis is accompanied by decreased
water and electrolyte absorption as well as transport of
fatty acids. DSS decreased I-FABP in the colon during
active disease and colonic enterocytes regain I-FABP
function during the regenerative phase [38]. These results
indicate that in the presence of SBI there is an attenuation
of epithelial injury in LF82/DSS-induced colitis.
Mucosal inflammation typically occurs after a compro-
mise in epithelial barrier and is another hallmark of chronic
and relapsing IBD. This study demonstrated attenuation of
DSS-induced inflammation in ASF mice colonized with
E. coli LF82 when SBI was administered compared to HC.
Evidence in reduced LF82/DSS-induced local inflamma-
tion was evident in histological sections of the GI tract
along with mucosal IL-6 production from cecal biopsies.
IL-6 is a pleiotropic cytokine that is secreted from many
cell types including macrophages, epithelial cells and T
cells following inflammatory insult and functions include
initiating the acute-phase response, activating SAA, and
activating lymphocytes to differentiate into Th17 cells [39,
40]. In IBD patients, there is a dysregulation of the IL-6
pathway that correlates with disease progression [39]. IL-6
along with TGFb help to differentiate effector Th17 cells
and if dysregulated, lead to an imbalance in effector/
regulatory T cell functions implicated in the pathogenesis
of chronic inflammation [41]. In this study, mucosal IL-6
production was reduced in the SBI administered LF82/DSS
mice compared with the HC, LF82/DSS group. Future
studies will address whether the decreased IL-6 production
was accompanied by a reduction in Th17 cells.
In addition, there was a reduction in several markers of
acute inflammation following SBI administration. SAA is
an acute-phase protein secreted by the liver and extrahep-
atic tissues, including the intestinal epithelium, and is
considered a biomarker for inflammation [42]. SAA has
been reported to be elevated in intestinal biopsies from CD
patients and has also been shown to be induced by IL-6
[43–45]. In murine models of IBD, SAA levels precede
clinical signs of inflammation as well as correlate with
Fig. 8 Evaluation of intestinal fatty-acid-binding protein (I-FABP).
I-FABP from plasma was analyzed as an indicator of intestinal
damage. E. coli LF82-colonized defined microbiota mice were treated
with hydrolyzed collagen (HC), HC ? DSS, serum-derived bovine
immunoglobulin/protein isolate (SBI), or SBI ? DSS. Plasma was
collected at necropsy and assayed for I-FABP by ELISA. Two-way
ANOVA indicated that I-FABP concentration was affected by both
the administration of DSS (p = 0.0093) and protein choice
(p = 0.0001). However, the interaction of the two variables on
I-FABP concentration was not significant (p = 0.4119). Further
analysis indicated that SBI significantly reduced I-FABP concentra-
tion in the LF82/DSS colitis model (HC ? LF82/DSS compared with
SBI ? LF82/DSS, p = 0.0003)
Fig. 9 Plasma serum amyloid A (SAA) levels as an indicator of
inflammation. E. coli LF82-colonized defined microbiota mice were
treated with hydrolyzed collagen (HC), HC ? DSS, serum-derived
bovine immunoglobulin/protein isolate (SBI), or SBI ? DSS. Plasma
was collected at necropsy and assayed for SAA by ELISA. Two-way
ANOVA indicated that SAA concentration was affected by both the
administration of DSS (p = 0.0008) and protein choice (p = 0.0031).
Also, the interaction of the two variables on SAA concentration was
significant (p = 0.0010). Further analysis indicated that SBI sig-
nificantly reduced SAA concentration in the LF82/DSS colitis model
(HC ? LF82/DSS compared with SBI ? LF82/DSS, p = 0.0006)
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increasing severity of DSS-induced inflammation [46, 47].
In this study, there was a reduction in inflammation as
evidenced by decreased levels of SAA when SBI was ad-
ministered to LF82/DSS mice compared with LF82/DSS
mice given HC.
Previous studies have shown that the immunoglobulin
component of SBI binds to bacterial antigens, including
MAMPS as well as bacterial toxins [22, 23]. In a transwell
co-culture model, SBI was shown to bind LPS, lipid A or
Pam3CSK4 on the apical surface to prevent subsequent
activation by THP-1 monocytes in the basal layer follow-
ing damage to the membrane [20]. Western blot analysis
presented herein demonstrates that SBI binds to multiple
antigens associated with all eight members of the ASF as
well as E. coli LF82. A hypothesis for the downstream
effect of SBI binding to luminal antigens in vivo is to
prevent these components from stimulating immune re-
sponses. Numerous reports exist in the literature explaining
how alterations of the microbiota correlate with inflam-
mation. The DSS model, along with other models of in-
duced or spontaneous colitis (e.g., IL-10-/- mice), have
reported that the resident microbiota has a central role in
modulating the severity of clinical signs [7, 48–55]. Ani-
mals reared in conventional compared to germfree envi-
ronments have increased evidence of inflammation.
Furthermore, mice genetically susceptible to IBD have a
reduction in severity of disease when treated with broad
spectrum antibiotics. The endpoints measured in the SBI
administered LF82/DSS mice indicate that SBI attenuated
epithelial damage and inflammation in comparison to the
HC administered LF82/DSS mice and are similar to what
would be expected based on studies reducing the damaging
effects of microbial components in a leaky gut. Thus, the
reduction in inflammation seen in SBI administered LF82/
DSS mice may be explained by the extrapolation of the
in vitro effects of SBI binding and preventing microbial
components from activating immune responses which
cause epithelial damage and inflammation.
Other experiments which utilized the DSS-induced colitis
model also demonstrated improved disease activity scores
and epithelial healing with oral bovine colostrum or serum
Igs [56]. Further analysis of the spleen in these studies
indicated that myeloid-derived suppressor cells (CD11b?-
Gr1?) that enhance recovery after colitis, were significantly
increased in sIgA-fed mice [56]. These results indicate that
the Ig component of bovine colostrum may have a positive
effect on the management of colitis. Bovine colostrum and
SBI are similar in that both contain growth factors and Igs;
however, SBI is more highly enriched for Igs [57, 58]. We
hypothesize that the Ig components within SBI may mod-
ulate inflammation by binding and preventing luminal anti-
gens from translocating across a permeabilized epithelium,
thereby reducing the recruitment of inflammatory effector
cells and indirectly helping to promote mucosal healing and
nutrient absorption. Future studies will assess the impact of
SBI on influencing regulatory cell recruitment following
LF82/DSS-induced inflammation.
In conclusion, a beneficial effect of SBI administration
was demonstrated in a mouse model of E. coli LF82 and
DSS-induced colitis. The Igs in SBI bound to antigens of
the enteric microbiota and daily administration of SBI re-
sulted in less damage and inflammation after challenging
with LF82/DSS. A control protein, HC, did not have the
same effect in this model suggesting the distinctive nature
of the protein nutrients in SBI are uniquely required to
manage the intestinal condition in this animal model of
colitis. The ability of SBI to maintain mucosal health
makes it an attractive agent to attenuate bacterial antigen-
induced GI inflammation associated with human IBD.
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